Precision Biologics, Inc.

𝑻𝒓𝒂𝒏𝒔𝒇𝒐𝒓𝒎𝒊𝒏𝒈 𝑹𝒆𝒔𝒆𝒂𝒓𝒄𝒉 𝒊𝒏𝒕𝒐 𝑹𝒆𝒂𝒍𝒊𝒕𝒚 Meet our distinguished speakers at the Drug Discovery Innovation Programme, 03-04 March 2025 in San Diego, CA! Join our industry-leading experts as they share breakthrough insights and cutting-edge developments shaping the future of drug discovery. 𝑫𝒐𝒏’𝒕 𝒎𝒊𝒔𝒔 𝒚𝒐𝒖𝒓 𝒄𝒉𝒂𝒏𝒄𝒆 𝒕𝒐 𝒍𝒆𝒂𝒓𝒏 𝒇𝒓𝒐𝒎 𝒂𝒏𝒅 𝒄𝒐𝒏𝒏𝒆𝒄𝒕 𝒘𝒊𝒕𝒉 𝒆𝒙𝒑𝒆𝒓𝒕𝒔 𝒂𝒕 𝒕𝒉𝒆 𝒇𝒐𝒓𝒆𝒇𝒓𝒐𝒏𝒕 𝒐𝒇 𝒊𝒏𝒏𝒐𝒗𝒂𝒕𝒊𝒐𝒏! 𝑹𝒆𝒔𝒆𝒓𝒗𝒆 𝒀𝒐𝒖𝒓 𝑷𝒍𝒂𝒄𝒆: https://bit.ly/3ZMI2GI 𝑭𝒐𝒓 𝑨𝒅𝒅𝒊𝒕𝒊𝒐𝒏𝒂𝒍 𝑸𝒖𝒆𝒓𝒊𝒆𝒔: https://bit.ly/4ac9Shb 𝑪𝒐𝒏𝒕𝒂𝒄𝒕 𝒖𝒔 𝒗𝒊𝒂 𝒆𝒎𝒂𝒊𝒍: info@worldbigroup.com #drugdiscovery #innovation #genomics #sciencestudent #steam #scientist #phdresearch #biologics #medicinalchem #drugdiscovery #oncology #bioinformatics #genomics #medicinalchemistry #drugdiscoveryconference2k25 #ddip2k25 Pranav Mathur | Cirsium Biosciences | A Anand Ojha, Ph.D. | Genentech | Zoran Krunic | Amgen | Philip M Arlen | Precision Biologics, Inc.

Precision Biologics, Inc. announces new US Patent filing on optimized antibody PB-223 Precision Biologics announces the filing of a new patent for our second asset, PB-223. This antibody recognizes Core 2 O-Glycans of variant MUC5AC antigen. PB-223 recognizes numerous human solid tumors but does not react to normal healthy surrounding tissue. To utilize how PB-223 targets a new class of tumor specific antigens, Precision Biologics is developing an antibody drug conjugate (ADC) for purposes of treating patients with refractory solid tumors. Information regarding this new asset will be presented at an international recognized meeting in the Fall of 2024, at which time Precision Biologics will release this data publicly

We are thrilled to announce that President & CEO of @precisionbiologics, Philip M Arlen, will deliver a keynote address at our upcoming Immuno US 2024 Conference! 🎤 Join us on October 28 to hear Philip share his experienced insights on Design & Development of Monoclonal Antibodies Against Novel Cancer Targets 🧬💡 This is an incredible opportunity to hear from a visionary leader. You won't want to miss this! Stay tuned for more updates. See you there! #OGImmuno #BiotechNews #HealthcareInnovation #CancerResearch #MedTech #PrecisionMedicine

Precision Biologics announces that a review, entitled "Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells", has been published on Expert Review of Vaccines on September 1st, 2024.  NEO-201 is our lead monoclonal antibody (mAb). The NEO-201 features described in this review are: ·      The generation of NEO-201 from the Hollinshead cancer vaccine platform ·      The characterization of the antigen recognized by NEO-201 ·      The ability of NEO-201 to bind and mediate the killing of cancer cells and immunosuppressive cells (gMDSCs and Tregs) through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) ·      NEO-201 preclinical and clinical toxicity and efficacy ·      The rationale to use NEO-201 in combination with cancer vaccines to synergize treatment efficacy One of the reasons for the limited clinical activity of cancer vaccines as monotherapy is the ability of cancer cells to secrete soluble factors and immunosuppressive cytokines, as well as to induce the increase of percentage of immunosuppressive cells, such as granulocytic myeloid-derived suppressor cells (gMDSCs) and regulatory T cells (Tregs), systemically and in the tumor microenvironment  (TME). These factors lead to the inhibition of the antitumoral activity of immune system components stimulated by cancer vaccines, including antibodies, T cells, NK cells. A potential strategy to overcome this issue may be the combination of cancer vaccines with NEO-201. NEO-201 can target and eliminate circulating Tregs and gMDSCs and may block the migration and accumulation of these cells in the TME. The capacity of NEO-201 to mediate the killing of human cancer cells and immunosuppressive cells expressing core 1 and/or extended core 1 O-glycans could allow cancer vaccines to stimulate a robust and durable immune adaptive response against cancer, improving their efficacy and the clinical response to immunotherapy in patients with several types of solid tumors. You can access to the full text of the review at the following link https://lnkd.in/dDBCEMjs

Looking forward to Immuno US 2024? 🌟 This year’s programme is set to explore the cutting-edge immune-targeting modalities that are revolutionizing patient care. From cell & gene therapies to therapeutic antibodies, vaccines, viruses, and the microbiome, we’re diving deep into the future of immunotherapy. Join us to hear from leading experts: 🔹Philip M Arlen from Precision Biologics, Inc. 🔹William Jai from Virogin Biotech 🔹Antonio F. Santidrian. Ph.D. from Calidi Biotherapeutics 🔹I-Ming Wang from Pfizer 🔹CARSTEN SCHMITZ MD/PhD from Eli Lilly and Company View more details: https://hubs.la/Q02LxNWx0 #OGImmuno #ImmunoUS2024 #Immunotherapy #Biotech #ClinicalTrials #InnovativeMedicine

Looking forward to Immuno US 2024? 🌟 This year’s programme is set to explore the cutting-edge immune-targeting modalities that are revolutionizing patient care. From cell & gene therapies to therapeutic antibodies, vaccines, viruses, and the microbiome, we’re diving deep into the future of immunotherapy. Join us to hear from leading experts: 🔹Philip M Arlen from Precision Biologics, Inc. 🔹William Jai from Virogin Biotech 🔹Antonio F. Santidrian. Ph.D. from Calidi Biotherapeutics 🔹I-Ming Wang from Pfizer 🔹CARSTEN SCHMITZ MD/PhD from Eli Lilly and Company View more details: https://hubs.la/Q02LxNWx0 #OGImmuno #ImmunoUS2024 #Immunotherapy #Biotech #ClinicalTrials #InnovativeMedicine

“Cancer Vaccines: New Targeting Strategies, Brighter Prospects”  An interview with Philip M Arlen, CEO and President of Precision Biologics, was included in a recent article describing the role of monoclonal antibodies in enhancing the effectiveness of cancer vaccines. This interview was published on August 1st, 2024, in the magazine Genetic Engineering and Biotechnology News, under the topic “Cancer Vaccines: New Targeting Strategies, Brighter Prospects”.     In this interview, Dr. Arlen explained the rationale of using monoclonal antibodies for boosting vaccine effectiveness, with a particular focus on the several mechanisms of action of our lead monoclonal antibody NEO-201. The ability of NEO-201 to specifically bind to and kill cells expressing truncated core 1 O-glycans, including immunosuppressive cells, makes NEO-201 a very promising immunotherapeutic. NEO-201 can mediate the killing of cancer cells but can also mediate the killing of immunosuppressive cells that impair the immune responses to immunotherapy and cancer vaccines. As a proof of this concept, preliminary correlative studies performed on blood samples from cancer patients with tumors refractory to prior immune checkpoint inhibitors, enrolled in our current phase 2 clinical trial combining NEO-201 with pembrolizumab, showed that NEO-201 led to a reduction in circulating immunosuppressive cells in cancer patients with durable stabilization of their disease. Given this clinical evidence, dr. Arlen suggests that “NEO-201 is ideal as a cocktail in combination with vaccines, checkpoint inhibitors, and anticancer drugs and that NEO-201 could really enhance the activity of these treatments by shutting down these immunosuppressive cells and allowing the treatments to work better.” To read the full article, please click on the link below https://lnkd.in/d3qm987U

Precision Biologics announces the United States Patent and Trademark Office (USPTO) has granted a Patent for its Lead Monoclonal Antibody, NEO-201, For Methods and Compositions for Targeting Treg Cells   NEO-201 is a humanized IgG1 monoclonal antibody with multiple mechanisms of action. It has been shown previously to kill cancer cells expressing its target (truncated Core 1 O-glycans). NEO-201 does not bind to most normal tissues. In addition, NEO-201 binds to and mediates the killing of immune suppressor cells, including regulatory T cells (Treg cells) and granulocytic myeloid-derived suppressor cells (gMDSCs), which are thought to diminish the efficacy of cancer immunotherapy. The patent granted by USPTO on July 16, 2024 (Patent No. US 12,037,410B2) describes the ability of NEO-201 to bind to Treg cells, and its use in targeting Treg cells. NEO-201 may also be used for isolation and detection of Treg cells. In addition, the patent claims that NEO-201 can mediate the killing of Treg cells through complement mediated cytotoxicity (CDC) in vitro. Therapeutic methods and combination therapies using NEO-201 in combination with another anti-cancer agent are also described in the patent.   Data from the ongoing Phase 2 trial, combining NEO-201 and Pembrolizumab in adults with solid tumors resistant to prior checkpoint inhibitors, were recently presented at ASCO Annual Meeting 2024 and demonstrated that NEO-201 reduces the quantity of Treg cells and gMDSCs in peripheral blood mononuclear cells (PBMCs) of cancer patients and that this reduction is associated with durable stabilization of disease.   The unique ability of NEO-201 to target and mediate the killing of both cancer cells and immunosuppressive cells, including Treg cells, makes NEO-201 a promising candidate to improve the efficacy of immunotherapy for the treatment of solid tumors expressing the target recognized by NEO-201. Additional information can be found at the following link https://lnkd.in/d4EnBysF

Precision Biologics announces that a Poster Presentation on novel findings from its ongoing phase 2 clinical trial, combining NEO-201 with pembrolizumab for the treatment of patients resistant to prior checkpoint inhibitor therapy, will be presented in a poster at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, McCormick Place Convention Center, Chicago, Illinois, USA, June 1st, 2024.  Poster title: Reduction of circulating naïve Tregs and gMDSCs and low levels of soluble MICA are prognostic for efficacy of combined NEO-201 and pembrolizumab The presentation of the poster will be made  in person at the McCormick Place Convention Center in Chicago, Illinois, USA, on Saturday June 1st, 2024, from 9am to 12pm. Please stop by Hall A, Session: Developmental Therapeutics-Immunotherapy, poster board #9, poster # 2530 to discuss these novel findings. Further details about these novel findings can be found in the PR from Precision Biologics at the following link https://lnkd.in/dvqP6MWb The PDF of the poster will be available starting from June 1st 2024 on https://lnkd.in/dJaaAjij

🔊 LAST CALL: SECURE YOUR SPOT AT THE 7TH INTERNATIONAL NEOANTIGEN SUMMIT 🔊 This is your FINAL chance to secure yourself an early bird pass and save up to €350 for the upcoming 7th International Neoantigen Summit (29th April-1st May). 🌍 Join our world class speaker faculty Alastair Hay Erkut Bahceci Dr. Dirk Hadaschik Jeroen Kneppers Maarten Slagter Jon Moore Alfred Slanetz Jian Yan, Ph. D. Wayne Paes Andrew Allen Mark A. Exley Giulia Longinotti Marc van Dijk Devabhaktuni Srikrishna Guido Leoni Mikkel Wandahl Pedersen Nicolas Poirier Eric Halioua Philip M Arlen Zelanna Goldberg, M.D., M.A.S. Martin Löwer Eniko Toke, PhD Paula R. Pohlmann Sari Pesonen Cedric Bogaert Christian Stumpp Bauke Anninga, PhD View the agenda here: https://lnkd.in/dckuyd2V For more info email: owen.carrick@hansonwade.com